Edwards Lifesciences is a global structural-heart specialist that completed the $4.2 billion sale of Critical Care to Becton, Dickinson on September 3, 2024, leaving a focused pure-play platform spanning TAVR, TMTT and Surgical Structural Heart. **TAVR remains the earnings base**, with Q2 2026 sales of $1.2583 billion, or 72.3% of continuing revenue, while TMTT provides the growth leg: sales rose 47.3% to $195.9 million. Q2 continuing-operations revenue was $1.741 billion, up 13.6% reported and 12.5% constant currency, beating consensus by $40 million; adjusted diluted EPS of $0.78 beat by $0.04. GAAP gross margin was 77.5% and adjusted operating margin 30.0%. Management raised 2026 constant-currency sales growth guidance to 10%–11%, increased revenue guidance to $6.6–$6.9 billion, and maintained adjusted EPS guidance of $2.95–$3.05. At approximately $89.95, valuation is demanding at 30.0x forward P/E and approximately 7.8x forward EV/Sales versus a 4.0x medical-device P/S average, but is supported by net cash of approximately $2.3 billion, market leadership and upcoming PROGRESS and Medicare catalysts.

Edwards Lifesciences Corp (EW) Investment Analysis

1. Executive Summary

Edwards Lifesciences Corporation is a pioneer and global leader in patient-focused medical innovations for structural heart disease [cite: 1, 2]. Historically recognized as the premier developer of transcatheter aortic valve replacement systems, the organization has recently streamlined its business model to focus exclusively on structural heart therapies [cite: 3, 4]. This strategic consolidation culminated in the completion of the sale of the Critical Care product group to Becton, Dickinson and Company on September 3, 2024, in an all-cash transaction valued at $4.2 billion [cite: 5, 6]. By shedding its patient monitoring segment, Edwards Lifesciences has repositioned itself as a pure-play structural heart platform, directing its capital, research capabilities, and commercial infrastructure toward high-growth, high-margin cardiovascular interventions [cite: 3, 7].

The corporation generates revenue across three primary, highly integrated structural heart segments:

• Transcatheter Aortic Valve Replacement (TAVR): This segment represents the core engine of the firm's portfolio [cite: 4, 8]. It centers on the minimally invasive SAPIEN family of balloon-expandable heart valves, which are designed to treat severe calcific aortic stenosis without the need for open-heart surgery [cite: 1, 9].
• Transcatheter Mitral and Tricuspid Therapies (TMTT): This rapid-growth division features repair and replacement platforms designed to address complex, underserved diseases of the mitral and tricuspid valves [cite: 2, 10]. Key commercial offerings include the PASCAL transcatheter edge-to-edge repair (TEER) system, the EVOQUE tricuspid valve replacement system, and the newly approved SAPIEN M3 transcatheter mitral valve replacement system [cite: 11, 12].
• Surgical Structural Heart: This mature, highly profitable business segment leverages the company’s decades-long history in traditional surgical cardiac valve replacement and repair [cite: 1, 13]. The portfolio is built around premium RESILIA tissue therapies—including the INSPIRIS, MITRIS, and KONECT devices—which utilize advanced tissue preservation technology to extend valve durability and minimize calcification [cite: 10].

Edwards Lifesciences generates revenue globally, with a balanced distribution between the United States and international markets, primarily Europe, Japan, and the wider Asia-Pacific region [cite: 10, 14, 15]. The primary customers for its technologies are healthcare systems, specialized hospitals, and academic medical centers [cite: 8, 16]. The actual purchasing decisions are heavily influenced by a multidisciplinary "Heart Team," consisting of interventional cardiologists, cardiothoracic surgeons, and echocardiographers [cite: 13, 17].

Clinicians choose Edwards Lifesciences over alternatives due to its industry-leading clinical trial evidence, which is highlighted by the multi-year PARTNER trials demonstrating SAPIEN’s long-term safety, low reintervention rates, and durability [cite: 3, 18]. Additionally, the company is preferred for the superior anti-calcification properties of its RESILIA tissue, its innovative delivery systems designed to facilitate coronary access, and its comprehensive, field-based clinical support teams that partner with heart centers globally to optimize patient outcomes [cite: 7, 13, 19].

---

2. Business Drivers & Strategic Overview

The economics of Edwards Lifesciences are driven by global demographic trends, innovative product cycles, and the expansion of clinical indications [cite: 13, 16]. The primary macroeconomic catalyst is an aging global population [cite: 16]. As the prevalence of valvular diseases rises exponentially in individuals over 60, the addressable patient population expands [cite: 16]. The primary revenue driver remains TAVR, which accounted for approximately 72% of total structural heart sales in recent periods [cite: 11, 20]. However, the strategic growth narrative is shifting toward a multi-platform paradigm where TMTT acts as a powerful secondary growth engine [cite: 4, 21].

                +---------------------------------------+
                |    EDWARDS LIFESCIENCES PLATFORM      |
                +---------------------------------------+
                                    |
         +--------------------------+--------------------------+
         |                          |                          |
+------------------+       +------------------+       +------------------+
|      TAVR        |       |      TMTT        |       |    SURGICAL      |
| SAPIEN 3 Ultra   |       | PASCAL / EVOQUE  |       | INSPIRIS / MITRIS|
|  RESILIA Valve   |       | SAPIEN M3 Valve  |       |  RESILIA Tissue  |
+------------------+       +------------------+       +------------------+
         |                          |                          |
         +--------------------------+--------------------------+
                                    |
                    +-------------------------------+
                    |  Dedicated Field Specialists  |
                    +-------------------------------+
                                    |
                    +-------------------------------+
                    | Heart Team clinical standard  |
                    +-------------------------------+

Core Product Portfolio and Technology Offerings

In the TAVR segment, the flagship technology is the SAPIEN 3 Ultra RESILIA valve [cite: 4, 10]. This platform combines a low-frame, balloon-expandable cobalt-chromium design with proprietary RESILIA tissue technology, which features advanced integrity preservation that eliminates free aldehydes and allows dry storage [cite: 10, 22]. Clinically, the low frame height is a critical design differentiator, allowing easier future access to the coronary arteries if a patient requires subsequent coronary interventions [cite: 19].

The TMTT segment targets a significantly larger, yet highly undertreated patient population suffering from mitral and tricuspid regurgitation [cite: 12, 21]. The PASCAL platform utilizes a catheter-delivered implant to grasp and clamp opposing valve leaflets, reducing regurgitation via edge-to-edge repair [cite: 12, 23]. The EVOQUE system represents a historic breakthrough as the first transcatheter therapy approved by the FDA for native tricuspid valve replacement [cite: 17, 22]. Operating through a transfemoral delivery sheath, EVOQUE replaces the diseased tricuspid valve to eliminate regurgitation [cite: 12, 24]. Additionally, the SAPIEN M3 platform offers a transcatheter mitral valve replacement option, providing a comprehensive repair-or-replace toolkit for complex valve pathologies [cite: 12].

In the Surgical segment, the focus is on utilizing premium RESILIA tissue across traditional surgical platforms [cite: 10, 12]. Products like the INSPIRIS aortic valve and MITRIS mitral valve are engineered to extend the durability of surgical bioprosthetic valves [cite: 10]. This is particularly beneficial for younger, active patients who wish to avoid the lifelong anticoagulation therapy required by mechanical valves, yet want to delay or avoid subsequent surgical reoperations [cite: 10, 19].

Moat Analysis

Edwards Lifesciences has established a wide economic moat, supported by multiple structural advantages:

• High Switching Costs: The deployment of transcatheter therapies requires intensive, hands-on training for interventional cardiologists, surgeons, and support staff [cite: 25]. Once a clinical heart team establishes high proficiency with the balloon-expandable SAPIEN platform, the cognitive and operational costs of switching to a competitor's self-expanding platform are substantial. Hospitals further standardize their procurement, inventory, and clinical protocols around a single preferred platform to maximize procedural efficiency and patient safety.
• Intellectual Property and Proprietary Technology: The firm’s proprietary anti-calcification RESILIA tissue platform is protected by a dense web of utility and manufacturing patents, preventing competitors from offering dry-storage, highly durable biological tissues.
• Clinical Evidence Moat: Clinical validation is a significant barrier to entry in the structural heart space [cite: 8, 26]. Edwards possesses an unmatched repository of long-term randomized clinical trial data [cite: 8]. The PARTNER trial series, spanning up to 10 years of patient follow-up, provides definitive proof of valve durability and clinical safety [cite: 3, 27]. This body of evidence is difficult for new entrants to replicate, as establishing comparable long-term clinical data requires a decade or more of clinical research.
• Regulatory and Scale Barriers: Obtaining pre-market approval (PMA) from the FDA and CE Mark approvals in Europe requires hundreds of millions of dollars in R&D and years of complex clinical trials [cite: 16, 25]. Edwards' global manufacturing footprint and direct, specialized sales force create an ecosystem that new competitors struggle to challenge.

Total Addressable Market (TAM) Analysis

The structural heart devices market is expanding rapidly, driven by clinical indication expansions and global market penetration [cite: 16, 28]. The global structural heart devices market was valued at approximately $7.20 billion in 2024 [cite: 16]. Industry forecasts project the market will expand at a compound annual growth rate (CAGR) of 13.5% to reach $33.80 billion by 2030, driven by the rapid adoption of minimally invasive transcatheter therapies [cite: 25].

Structural Heart Devices Global TAM Forecasts:
  - 2024: $7.20 Billion [cite: 16]
  - 2025: $18.30 Billion [cite: 25]
  - 2030: $33.80 Billion [cite: 25]
  - 2035: $65.00 Billion [cite: 25]

Specifically within the TAVR market, the global market is projected to reach $13.35 billion by 2030, growing at an estimated CAGR of over 13% [cite: 29]. This growth is driven by several key factors:

• Asymptomatic Patients: The expansion of TAVR to treat asymptomatic severe aortic stenosis patients, supported by positive data from the EARLY TAVR clinical trial, has significantly increased the addressable patient pool [cite: 3, 7].
• Moderate Aortic Stenosis: The PROGRESS trial is evaluating whether patients with moderate aortic stenosis and at-risk features can benefit from early TAVR intervention, potentially expanding the market to a broader, earlier-stage patient demographic [cite: 8, 30].
• TMTT Opportunity: The transcatheter mitral and tricuspid markets remain largely untapped [cite: 12]. Edwards projects that the global TMTT market opportunity will reach $2.0 billion by 2030, driven by the clinical adoption of EVOQUE and next-generation repair devices [cite: 2, 27].

Competitive Landscape

The global TAVR and structural heart market operates as a highly consolidated oligopoly [cite: 18]. The competitive dynamics and positioning of the four key players are detailed in the table below:

Competitor	Market Share & Positioning	Competitive Advantages / Technological Focus	Trajectory vs. Edwards
Edwards Lifesciences [cite: 31]	Market leader with >60% global TAVR share and ~75% U.S. share [cite: 24].	Balloon-expandable platforms (SAPIEN) [cite: 24]; RESILIA tissue technology [cite: 10]; extensive long-term clinical data [cite: 8].	Holding ground in core areas [cite: 24], while capturing share in tricuspid replacement (EVOQUE first-mover advantage) [cite: 12, 17].
Medtronic [cite: 31]	Primary global challenger [cite: 18].	Self-expanding supra-annular platforms (Evolut FX+) [cite: 24]. Superior hemodynamics in small-annulus patients (SMART trial) [cite: 24].	Medtronic has faced challenges, including leadership shifts and product execution issues [cite: 18]. These struggles present an opportunity for Edwards to capture 15% to 20% of Medtronic's market share in high-volume clinics [cite: 18].
Abbott Laboratories [cite: 31]	Established structural heart player [cite: 32].	Navitor self-expanding TAVR platform [cite: 32, 33] and MitraClip market leadership in mitral repair [cite: 32]. Developing balloon-expandable systems [cite: 32].	Holding market position [cite: 33], but faces pressure as Edwards scales its TMTT repair-and-replace portfolio [cite: 12, 34].
Boston Scientific [cite: 31]	Emerging challenger [cite: 24].	Exited TAVR directly by halting Acurate neo2 and Prime in mid-2025 due to regulatory hurdles [cite: 23, 32]. Re-entering via a $1.5B investment and $3.0B option to acquire MiRus (SIEGEL balloon-expandable TAVR) [cite: 23, 24].	Currently losing direct market ground, but poses a long-term threat if the MiRus SIEGEL platform completes its STAR pivotal trial [cite: 24].

---

3. Financial Performance & Valuation

Edwards Lifesciences' financial model is characterized by high gross margins, disciplined operating leverage, and robust cash generation, which supports ongoing reinvestment in R&D [cite: 8, 11].

Q2 2026 Earnings Analysis

The company reported its second-quarter 2026 financial results on July 23, 2026, demonstrating strong operational execution across its structural heart portfolio [cite: 8].

• Topline Revenue: Net sales from continuing operations reached $1.741 billion, representing a 13.6% year-over-year increase on a GAAP basis, or 12.5% on a constant currency basis [cite: 11, 20]. This surpassed consensus analyst expectations of $1.70 billion by 2.35% (a $40 million beat) [cite: 8]. Topline growth was driven by TAVR sales of $1.258 billion (up 11.3 reported, 10.5% constant currency) and a 47.3% surge in TMTT sales to $195.9 million (44.8% constant currency) [cite: 10, 11, 20].
• Earnings Per Share (EPS): Non-GAAP adjusted diluted EPS from continuing operations was $0.78, beating consensus estimates of $0.74 by 5.4% (a $0.04 beat) [cite: 8, 11]. However, GAAP diluted EPS from continuing operations fell to $0.42, down from $0.57 in Q2 2025 [cite: 20, 35]. This decline was driven by a $188.2 million non-cash valuation allowance on deferred tax assets due to a California tax credit law change, as well as a $40.0 million asset impairment charge related to a variable-interest entity investment [cite: 20].
• Profitability Metrics: Gross profit margin was stable, with a GAAP gross margin of 77.5% and an adjusted gross margin of 77.6% [cite: 11, 28]. Operating profit margin reached 29.5% on a GAAP basis and 30.0% on an adjusted basis, up from 26.8% GAAP in the prior year, driven by favorable product mix and the strategic timing of investments [cite: 20, 28].
• Guidance Adjustments: Management raised its full-year 2026 constant currency sales growth guidance to 10%–11% (up from 9%–11%) and increased its total projected revenue range to $6.6 billion to $6.9 billion [cite: 8, 20]. TAVR constant currency growth expectations were increased to 8%–9% (from 7%–9%), and TMTT full-year sales guidance was raised to $760–$780 million [cite: 10, 20]. Despite the higher expected tax rate (at the high end of the 16%–19% range), the company reaffirmed its full-year adjusted EPS guidance of $2.95 to $3.05, representing approximately 17% growth at the midpoint from the prior year [cite: 10, 28].

Q2 2026 Revenue Contribution by Segment:
  - TAVR: $1,258.3 Million (72.3%) [cite: 11, 20]
  - TMTT: $195.9 Million (11.2%) [cite: 10, 20]
  - Surgical: $284.1 Million (16.3%) [cite: 20]
  - Total Continuing Ops: $1,741.0 Million (100%) [cite: 11, 20]

Market Reaction and Executive Commentary

The market responded positively to the Q2 2026 earnings release, and the stock rose 4.99% in after-hours trading, climbing from a regular session close of $83.82 to $88.00 [cite: 8]. Investors focused on the topline beat and raised revenue guidance, which helped ease concerns about procedural growth and hospital utilization [cite: 8, 36]. BTIG and Stifel analysts reiterated their Buy ratings, citing the upcoming PROGRESS moderate AS data readout and a favorable Medicare coverage review as key potential catalysts [cite: 36, 37].

In the earnings call, CEO Bernard Zovighian emphasized the benefits of the firm's multi-platform structural heart strategy [cite: 8]. He highlighted that the company's profile has evolved to support durable, multi-year growth across multiple therapeutic areas [cite: 35]. CFO Doretta Mistras, in her first earnings call since taking office on May 29, 2026, confirmed that strong operational execution and robust underlying structural heart fundamentals supported the company's positive guidance revision [cite: 8, 38, 39].

Financial Drivers and Valuation

Edwards Lifesciences has delivered a steady 5-year sales CAGR of approximately 10.5% (adjusted for continuing operations), reflecting the clinical adoption of its transcatheter platforms [cite: 3, 14, 40]. The historical financial results of the company are presented in the table below:

Metric (USD Millions)	FY 2023	FY 2024	FY 2025	LTM (Ending Q2 2026)
Net Sales (Continuing Ops)	$5,010.0 [cite: 41]	$5,439.5 [cite: 41]	$6,065.0 [cite: 42]	$6,500.0 [cite: 43]
Gross Profit Margin (GAAP)	78.4% [cite: 44]	77.5% [cite: 12]	78.1% [cite: 45]	77.5% [cite: 11]
Operating Income (GAAP)	$1,345.0	$1,228.0	$1,113.1 [cite: 46]	$1,820.0 [cite: 43]
GAAP Net Income (Continuing Ops)	$1,151.0	$1,070.0 [cite: 47]	$991.8 [cite: 46]	$1,001.0 [cite: 43]
Adjusted Diluted EPS	$2.51 [cite: 22]	$2.63	$2.56 [cite: 48]	$2.92

Capital Structure as of June 30, 2026:
  - Cash & Cash Equivalents: $2.90 Billion [cite: 10, 20]
  - Total Outstanding Debt: $600 Million [cite: 10, 20]
  - Remaining Share Buyback Authorization: $1.50 Billion [cite: 10, 20]

At a share price of approximately $89.95, Edwards Lifesciences commands an equity market capitalization of $52.1 billion [cite: 49, 50]. Based on the midpoint of FY 2026 adjusted EPS guidance of $3.00, the stock trades at a forward P/E multiple of 30.0x [cite: 10, 47]. The company's enterprise value-to-sales (EV/Sales) multiple is approximately 7.8x on a forward basis [cite: 43].

This valuation represents a premium compared to the broader medical device sector, which trades at an average P/S of 4.0x [cite: 43]. This premium is supported by several core characteristics of the business model:

• Pure-Play Structural Heart Exposure: Following the divestiture of its Critical Care segment, Edwards is uniquely positioned as a pure-play investment in high-growth, high-margin structural heart therapies [cite: 3, 6].
• Superior Profitability: The company generates strong adjusted gross profit margins of 77.5% to 78% and an adjusted operating margin of 30.0%, which is well above the average for medical technology companies [cite: 11, 20, 28].
• Balance Sheet Strength: With a net cash position of approximately $2.3 billion ($2.9 billion in cash versus $600 million in debt), the company has significant financial flexibility [cite: 10, 20]. This cash position supports ongoing share buybacks, such as the recently completed $500 million accelerated share repurchase, as well as strategic acquisitions to fuel long-term growth [cite: 28, 51].

---

4. Risk Assessment & Macroeconomic Considerations

As a pure-play structural heart company, Edwards Lifesciences' risk profile is concentrated on clinical execution, regulatory approvals, and competitive dynamics [cite: 3, 18].

                     +----------------------------------------+
                     |         CORE SYSTEMIC RISKS            |
                     +----------------------------------------+
                                         |
         +-------------------------------+-------------------------------+
         |                               |                               |
+-------------------+          +-------------------+           +-------------------+
|  Clinical Risk    |          |  Competitive Risk |           | Regulatory Risk   |
| Failing PROGRESS  |          | Boston Scientific |           | Shifting Medicare |
| Or asymptomatic   |          |  re-entry with    |           |  reimbursement    |
|   clinical trials |          |  MiRus SIEGEL     |           |   NCD reviews     |
+-------------------+          +-------------------+           +-------------------+

Risk Matrix and Breakdown

• Company-Specific Execution Risks: The primary execution risk is the commercial ramp of the TMTT portfolio [cite: 7]. Managing a direct sales force to drive clinical adoption of EVOQUE and SAPIEN M3 in Europe and the U.S. requires significant capital and precise execution [cite: 7, 12]. Suboptimal execution could lead to rising SG&A expenses without a corresponding increase in revenue, putting pressure on operating margins [cite: 8, 14]. Additionally, transitioning leadership during the CFO succession of Doretta Mistras introduces potential execution risks in capital allocation and financial planning [cite: 38, 39].
• Competitive Risks: While Edwards currently leads the global TAVR market, competitor advancements pose a threat [cite: 24, 33]. Medtronic's Evolut FX+ platform has shown favorable clinical data in small-annulus patients, particularly women [cite: 24]. Additionally, Boston Scientific's exclusive option to acquire the MiRus SIEGEL balloon-expandable TAVR system represents a potential competitor in Edwards' core balloon-expandable market segment [cite: 23, 24].
• Regulatory and Legal Risks: Structural heart innovations require pre-market approval (PMA) and clinical trial clearances [cite: 16]. Any safety signals, such as thrombosis-related valve dysfunction identified in clinical follow-ups, could lead to regulatory restrictions or negative labels [cite: 18, 19]. Additionally, the company faces patent litigation risks, as highlighted by its disputes with competitors like Cardiovalve [cite: 52].
• Macroeconomic and Financial Sensitivities: Because a significant portion of manufacturing occurs in the United States while international sales are denominated in local currencies, the company is sensitive to foreign exchange fluctuations [cite: 10, 11]. Weakening local currencies relative to the U.S. dollar create margin headwinds that can impact the company's financial results [cite: 10, 11]. Furthermore, localized changes in corporate tax laws—such as California's recent restrictions on R&D tax credit utilization—can impact net income and the GAAP effective tax rate [cite: 20].

Vulnerability Analysis

• What Could Go Wrong: In a worst-case scenario, the PROGRESS clinical trial evaluating moderate aortic stenosis could fail to meet its primary endpoints, or the FDA could delay expanding the SAPIEN label [cite: 8, 30]. This clinical failure would prevent access to a significant potential patient population and could cause TAVR growth to flatten [cite: 13, 36]. Simultaneously, Boston Scientific could execute its option to acquire MiRus, introducing a highly competitive balloon-expandable platform that erodes SAPIEN’s core market share [cite: 23, 24].
• Early Warning Signs: Key metrics for investors to monitor include a deceleration in TAVR constant currency growth to the mid-single digits, which would indicate potential market saturation or share loss to competitors [cite: 13, 33]. Additionally, a persistent decline in gross profit margin below the historical 78% threshold, driven by pricing pressure from hospital standardizations, would signal eroding pricing power [cite: 10, 11]. Investors should also monitor any delays in Medicare’s National Coverage Determination (NCD) updates regarding asymptomatic patients [cite: 8].
• Long-Term Thesis Damage: The long-term investment thesis would be impaired if transcatheter therapies lost clinical favor due to long-term safety concerns, such as accelerated structural valve deterioration compared to traditional surgical tissue valves [cite: 9, 18]. If clinical guidelines shifted back to surgical intervention or prolonged clinical surveillance, the growth runway for TAVR and TMTT would contract, leading to a down-rating of the stock's valuation multiple [cite: 25, 30].

---

5. 5-Year Scenario Analysis

The 5-year scenario analysis projects the potential valuation outcomes for Edwards Lifesciences from 2026 to 2031, using a current base share price of $89.95 [cite: 49].

Projected Share Price Trajectory (USD) over 5 Years:
  - High Case:  $167.70 [86.4% Total Return]
  - Base Case:  $111.25 [23.7% Total Return]
  - Low Case:   $51.84  [-42.4% Total Return]

High Case (25% Probability)

The High Case assumes that TAVR growth accelerates, supported by positive PROGRESS trial data that expands the addressable patient population to include moderate aortic stenosis [cite: 8, 30]. It also assumes the rapid rollout of the asymptomatic indication under updated Medicare NCD rules [cite: 8]. Under this scenario, TMTT therapies exceed expectations, driven by the global adoption of EVOQUE and SAPIEN M3, pushing TMTT revenues beyond $2.5 billion by 2030 [cite: 2, 12].

• Five-Year Sales CAGR: 12.0%
• Year 5 Revenue (2031): $11.89 billion (using a 2026 revenue base of $6.75 billion) [cite: 8, 20]
• Adjusted Net Margin: 24.0% (reflecting high operating leverage and the normalization of corporate tax rates) [cite: 8, 28]
• Outstanding Shares: 510 million (assuming aggressive share repurchases using strong free cash flow and cash reserves) [cite: 10, 20]
• Adjusted Diluted EPS: $5.59
• Exit Multiple (P/E): 30.0x (reflecting a sustained valuation premium due to double-digit structural heart growth) [cite: 1, 43]
• Implied Share Price (2031): $167.70 USD
• Five-Year Total Return: 86.44%
• Annualized Return: 13.27%

Base Case (60% Probability)

The Base Case assumes that Edwards Lifesciences maintains its market-leading position in the TAVR space, with stable pricing and procedural growth in the high-single digits [cite: 7, 13]. This growth is supported by clinical guideline updates and the gradual adoption of asymptomatic treatments [cite: 13, 33]. The TMTT segment scales in line with management's expectations, reaching $2.0 billion in sales by 2030, driven by the rollout of PASCAL and EVOQUE [cite: 2, 27].

• Five-Year Sales CAGR: 10.0% [cite: 8, 28]
• Year 5 Revenue (2031): $10.87 billion [cite: 8, 20]
• Adjusted Net Margin: 22.0% (assumes steady operating margin expansion of 50-100 bps annually, offset by foreign exchange headwinds) [cite: 11, 28]
• Outstanding Shares: 537 million (reflecting historical share buybacks utilizing the remaining share repurchase authorization) [cite: 10, 20]
• Adjusted Diluted EPS: $4.45
• Exit Multiple (P/E): 25.0x (assumes multiple compression as the TAVR market matures) [cite: 43]
• Implied Share Price (2031): $111.25 USD
• Five-Year Total Return: 23.68%
• Annualized Return: 4.34%

Low Case (15% Probability)

The Low Case assumes that TAVR growth slows to the mid-single digits due to competition from Medtronic’s self-expanding platforms and Boston Scientific's re-entry into the balloon-expandable market [cite: 24, 33]. This scenario also assumes that clinical data from the PROGRESS trial is inconclusive, limiting label expansion [cite: 8, 30]. Additionally, TMTT adoption slows due to clinical training bottlenecks, and foreign exchange fluctuations create ongoing margin headwinds [cite: 10, 11, 25].

• Five-Year Sales CAGR: 6.0%
• Year 5 Revenue (2031): $9.03 billion [cite: 8, 20]
• Adjusted Net Margin: 18.0% (reflecting pricing compression on SAPIEN valves and elevated SG&A requirements) [cite: 7, 10]
• Outstanding Shares: 565 million (assumes limited share buybacks as cash is preserved for R&D) [cite: 8, 10]
• Adjusted Diluted EPS: $2.88
• Exit Multiple (P/E): 18.0x (reflecting a down-rating of the stock to align with slower-growing diversified medical technology peers) [cite: 43]
• Implied Share Price (2031): $51.84 USD
• Five-Year Total Return: -42.37%
• Annualized Return: -10.45%

Share Price Trajectory (USD) over 5 Years

The table below outlines the share price trajectory under each of the three scenarios, showing the projected price movement from Year 0 through Year 5:

Year	High Case (USD)	Base Case (USD)	Low Case (USD)
Year 0 (2026)	$89.95 [cite: 49]	$89.95 [cite: 49]	$89.95 [cite: 49]
Year 1 (2027)	$101.40	$93.85	$80.50
Year 2 (2028)	$114.90	$97.90	$72.05
Year 3 (2029)	$130.20	$102.15	$64.50
Year 4 (2030)	$147.50	$106.60	$57.75
Year 5 (2031)	$167.70	$111.25	$51.84

Scenario Analysis Summary Table

The key financial assumptions and projected returns across the three scenarios are summarized below:

Scenario	Year 5 Revenue (USD Billion) [cite: 8, 20]	Net Margin / EPS	Exit P/E Multiple [cite: 43]	Current Price (USD) [cite: 49]	Projected Year 5 Price (USD)	5-Year Total Return	Annualized Return	Subjective Probability
High Case	$11.89	24.0% / $5.59	30.0x	$89.95	$167.70	86.44%	13.27%	25%
Base Case	$10.87	22.0% / $4.45	25.0x	$89.95	$111.25	23.68%	4.34%	60%
Low Case	$9.03	18.0% / $2.88	18.0x	$89.95	$51.84	-42.37%	-10.45%	15%
Weighted	$10.85	21.9% / $4.50	25.2x	$89.95	$116.45	29.46%	5.30%	100%

ASYMMETRIC GROWTH POTENTIAL

---

6. Qualitative Scorecard

To evaluate the operational, clinical, and financial strength of Edwards Lifesciences, the following scorecard rates key qualitative metrics on a scale of 1 to 10:

Qualitative Scorecard Ratings (1-10 Scale):
  - Profitability:          9/10
  - Financial Health:       9/10
  - Track Record:           9/10
  - Revenue Quality:        9/10
  - Analyst Sentiment:      9/10
  - Capital Allocation:     8/10
  - Business Viability:     8/10
  - Management Alignment:   8/10
  - Growth Outlook:         8/10
  - Market Position:        7/10
  ---------------------------------
  OVERALL BLENDED SCORE:   8.4/10

• Profitability (9/10): The company continues to generate strong margins, with a GAAP gross margin of 77.5% and an adjusted operating margin of 30.0% in its continuing operations [cite: 11, 20, 28]. Favorable product mix and the high average selling prices of SAPIEN and EVOQUE valves support premium profitability [cite: 12, 13].
• Financial Health (9/10): The balance sheet remains a key credit strength, with approximately $2.90 billion in cash and cash equivalents against only $600 million in outstanding debt [cite: 10, 20]. This net cash position provides a strong safety buffer and significant financial flexibility [cite: 4].
• Track Record (9/10): With over 70 years of innovation in heart valve therapies, the firm has a history of creating new product categories and establishing clinical standards of care [cite: 1, 3]. This history has generated long-term shareholder value and established strong relationships with cardiovascular clinics globally [cite: 8, 26].
• Revenue Quality (9/10): Following the divestiture of its Critical Care segment, the company's revenue is highly focused on clinical-choice, implantable heart valves [cite: 3, 6]. Customer concentration is extremely low, as purchasing is distributed across thousands of cardiac care hospitals worldwide [cite: 8, 16].
• Analyst Sentiment (9/10): Sell-side sentiment remains positive, with 21 Buy ratings, 7 Holds, and 0 Sells [cite: 53]. Analysts from Evercore ISI, BTIG, and Stifel have highlighted the firm’s competitive positioning and upcoming clinical catalysts as key positive factors [cite: 36, 37].
• Capital Allocation (8/10): The divestiture of Critical Care for $4.2 billion in cash demonstrates active portfolio management to focus on higher-growth structural heart opportunities [cite: 3, 6]. Capital return remains strong, as highlighted by a recently completed $500 million accelerated share repurchase program and $1.5 billion remaining under current authorizations [cite: 10, 51]. However, the regulatory block of the JenaValve acquisition represents a minor setback in the company’s capital deployment strategy [cite: 18, 52].
• Business Viability (8/10): The core business model is supported by long-term clinical trial data, establishing a highly durable franchise [cite: 3, 27]. The primary limitation is the specialized nature of these cardiac procedures, which require trained heart teams and dedicated clinical infrastructure to support adoption [cite: 17, 25].
• Management Alignment (8/10): Executive compensation is aligned with shareholder interests, with over 90% of CEO Bernard Zovighian’s compensation tied to performance bonuses and equity-based awards [cite: 52]. Insiders collectively hold a significant stake in the business [cite: 52]. However, the presence of pre-planned 10b5-1 insider stock sales can sometimes affect short-term investor sentiment [cite: 54, 55].
• Growth Outlook (8/10): While the core TAVR market is maturing, growth is supported by clinical indication expansions into asymptomatic and moderate AS patients [cite: 21, 30]. TMTT therapies represent a high-growth opportunity that is projected to reach $2.0 billion in sales by 2030 [cite: 2, 27].
• Market Position (7/10): Edwards maintains its leading market position, commanding over 60% of the global TAVR market and ~75% of the U.S. market [cite: 24]. However, the company faces clinical competition from Medtronic’s self-expanding platforms, as shown in the head-to-head SMART trial, and the potential re-entry of Boston Scientific with the MiRus platform [cite: 23, 24].

Overall Blended Score: 8.4 / 10

HIGH-QUALITY STRUCTURAL LEADER

---

7. Conclusion & Investment Thesis

The long-term investment thesis for Edwards Lifesciences is built on its transition to a pure-play structural heart company [cite: 3, 42]. Following the sale of its Critical Care segment, the company has concentrated its resources and capital on high-margin, clinically differentiated transcatheter platforms [cite: 3, 6].

                 +----------------------------------------+
                 |       LONG-TERM VALUE CREATION         |
                 +----------------------------------------+
                                     |
         +---------------------------+---------------------------+
         |                           |                           |
+-------------------+       +-------------------+       +-------------------+
| CLINICAL EVIDENCE |       | MULTI-PLATFORM CC |       | STRONG FINANCIALS |
| Durable standard  |       | Mitral/Tricuspid  |       | Cash-rich balance |
| of care; PARTNER  |       | EVOQUE / PASCAL   |       | sheet supporting  |
| data [cite: 3]   |       | expansion [cite: 10]|       |  buybacks [cite: 10]|
+-------------------+       +-------------------+       +-------------------+

The long-term growth narrative is supported by three primary pillars:

1. Clinical Durability and Standard of Care: The SAPIEN TAVR platform is supported by extensive clinical evidence, including 7-year and 10-year follow-up data from the PARTNER trials [cite: 3, 27]. This data establishes SAPIEN as a clinical standard of care for severe aortic stenosis, creating high clinical switching costs and brand loyalty [cite: 1, 9].
2. Multi-Platform Structural Expansion: The TMTT segment provides a significant secondary growth driver [cite: 4, 21]. With EVOQUE established as the first-of-its-kind FDA-approved tricuspid replacement system and the SAPIEN M3 platform expanding mitral options, Edwards is positioned to capture a large share of the underserved mitral and tricuspid markets [cite: 12, 17].
3. Strong Financial Profile: The company's high gross margins (~77.5%), net cash position of approximately $2.3 billion, and consistent share repurchases support a premium valuation compared to diversified medical technology peers [cite: 10, 11, 43]. This financial strength allows the company to invest in clinical trials, such as the PROGRESS study, which could expand the addressable market to include moderate aortic stenosis and drive long-term revenue growth [cite: 8, 30].

While the company faces competition from Medtronic's self-expanding systems and the potential re-entry of Boston Scientific, its direct clinical support teams and established hospital relationships provide a strong competitive buffer [cite: 13, 24]. Edwards Lifesciences remains a high-quality structural heart innovator, well-positioned to benefit from favorable demographic trends and the expansion of transcatheter therapies [cite: 16, 21].

PREMIER STRUCTURAL PLATFORM

---

8. Technical Analysis, Price Action & Short-Term Outlook

Edwards Lifesciences (NYSE: EW) exhibits a positive technical structure, with the stock trading at $89.95 as of August 27, 2026 [cite: 49]. This current price positions the stock above its key 50-day simple moving average of $89.09 and its 200-day simple moving average of $84.68, confirming a bullish trend [cite: 56].

Technical Trend Indicators (August 2026):
  - Current Share Price:          $89.95 [cite: 49]
  - 50-Day Simple Moving Average:  $89.09 [cite: 56]
  - 200-Day Simple Moving Average: $84.68 [cite: 56]
  - Technical Trend:              BULLISH [cite: 57]

The stock’s upward momentum is supported by the Q2 2026 earnings beat and raised full-year sales guidance, which has increased investor confidence during the leadership transition to CFO Doretta Mistras [cite: 8, 39]. In the short term, the technical picture suggests strong support near the $84.00 level, while the next target is key resistance near the 52-week high of $96.29 [cite: 8, 49]. The technical trend remains constructive, driven by solid structural heart fundamentals and several upcoming clinical catalysts [cite: 8].

TECHNICAL MOMENTUM SUSTAINED

---

1. Edwards Lifesciences Corporation Q1 F2026 Earnings Call Transcript, https://www.earningswhispers.com/transcript/EW
2. Edwards Lifesciences Reaffirms Strategy for Sustainable, Differentiated Growth at Annual Investor Conference, https://www.edwards.com/newsroom/news/2025-12-04-edwards-lifesciences-reaffirms-strategy-for-sustai
3. Edwards Lifesciences Reports Fourth Quarter Results, https://ir.edwards.com/news/news-details/2026/Edwards-Lifesciences-Reports-Fourth-Quarter-Results/default.aspx
4. Edwards Lifesciences (EW) Has a Structural-Heart Platform Bigger Than a Single-Procedure Trade - Alphastreet, https://news.alphastreet.com/edwards-lifesciences-ew-has-a-structural-heart-platform-bigger-than-a-single-procedure-trade/
5. Edwards Lifesciences Completes Sale of Critical Care Business to Becton, Dickinson and Company - Cassels, https://cassels.com/rep_work/edwards-lifesciences-completes-sale-of-critical-care-business-to-becton-dickinson-and-company/
6. Edwards Lifesciences Completes Sale of Critical Care, https://www.edwards.com/newsroom/news/2024-09-03-edwards-lifesciences-completes-sale-of-critical-ca
7. Edwards Lifesciences Reports Fourth Quarter Results, https://ir.edwards.com/news/news-details/2025/Edwards-Lifesciences-Reports-Fourth-Quarter-Results/default.aspx
8. Earnings call transcript: Edwards Lifesciences tops Q2 2026 estimates, lifts sales outlook, https://www.investing.com/news/transcripts/earnings-call-transcript-edwards-lifesciences-tops-q2-2026-estimates-lifts-sales-outlook-93CH-4810203
9. Outcomes finder | Edwards Lifesciences, https://www.edwards.com/patients-care-partners/clinical-research-trials/outcomes-finder
10. Financial Results - Edwards Lifesciences Corp, https://ir.edwards.com/financials/financial-results/
11. EWL - Edwards Lifesciences Corp Earnings Reports, Summaries & Call Transcripts, https://www.morningstar.com/stocks/xstu/ewl/earnings
12. Edwards Lifesciences Reports Second Quarter Results, https://ir.edwards.com/news/news-details/2025/Edwards-Lifesciences-Reports-Second-Quarter-Results/
13. Edwards Lifesciences Reports First Quarter Results, https://ir.edwards.com/news/news-details/2026/Edwards-Lifesciences-Reports-First-Quarter-Results/default.aspx
14. Edwards Lifesciences Reports Fourth Quarter Results, https://s27.q4cdn.com/788244549/files/doc_news/Edwards-Lifesciences-Reports-Fourth-Quarter-Results-2026.pdf
15. Edwards Lifesciences - SEC.gov, https://www.sec.gov/Archives/edgar/data/1099800/000109980026000038/ex-991q22026.htm
16. Structural Heart Devices Market Size and Outlook 2030 - TechSci Research, https://www.techsciresearch.com/report/structural-heart-devices-market/21764.html
17. Edwards Lifesciences Reports First Quarter Results, https://www.edwards.com/newsroom/news/2025-04-23-edwards-lifesciences-reports-first-quarter-results-1c842a9
18. Edwards Lifesciences' SWOT analysis: stock gains momentum on market share opportunity, https://www.investing.com/news/swot-analysis/edwards-lifesciences-swot-analysis-stock-gains-momentum-on-market-share-opportunity-93CH-4780482
19. Transcatheter Aortic Valve Replacement - Edwards Lifesciences, https://www.edwards.com/healthcare-professionals/conditions-procedures/tavr/transcatheter-aortic-valve-replacement
20. Edwards Lifesciences (NYSE: EW) lifts 2026 outlook after strong Q2 growth, https://www.stocktitan.net/sec-filings/EW/8-k-edwards-lifesciences-corp-reports-material-event-a68d9638e0f4.html
21. Edwards Lifesciences Outlines Growth Strategy at Annual Investor Conference, https://www.edwards.com/sg/newsroom/news/2024-12-04-edwards-lifesciences-outlines-growth-strategy-at-a-26ec645
22. Edwards Lifesciences Reports Fourth Quarter Results, https://ir.edwards.com/news/news-details/2024/Edwards-Lifesciences-Reports-Fourth-Quarter-Results/default.aspx
23. Edwards TAVR Data Shines at New York Valves 2026, https://www.mddionline.com/cardiovascular/edwards-unveils-strong-tavr-results-at-ny-valves-2026
24. Medtronic vs. Edwards: Head-to-Head in the TAVR Arena - VCBeat, https://www.vcbeathealth.com/article/11076
25. Structural Heart Devices Market | Global Market Analysis Report - 2035, https://www.futuremarketinsights.com/reports/structural-heart-devices-market
26. Edwards Lifesciences Corp Q4 2026 Earnings Call Transcript | Full Text - EarningsCall.ai, https://www.earningscall.ai/stock/transcript/EW-2026-Q4
27. Edwards Lifesciences (EW) Earnings Transcript | The Motley Fool, https://www.fool.com/earnings/call-transcripts/2025/11/27/edwards-lifesciences-ew-earnings-transcript/
28. Edwards Lifesciences (EW) Q2 2026 earnings summary - Quartr, https://quartr.com/events/edwards-lifesciences-ew-q2-2026_3PpeN0ZW
29. Transcatheter Aortic Valve Replacement Market Analysis - 2030, https://www.strategicmarketresearch.com/market-report/transcatheter-aortic-valve-replacement-market
30. Edwards' Structural Heart Leadership Demonstrated Through Expanding Body of Scientific Evidence at New York Valves, https://www.edwards.com/newsroom/news/2026-06-26-edwards--structural-heart-leadership-demonstrated-
31. Edwards Lifesciences competitors - Distill Intelligence, https://www.distillintelligence.com/competitors/edwards-lifesciences
32. Abbott eyes structural heart gains following Boston Scientific's TAVR exit - Fierce Biotech, https://www.fiercebiotech.com/medtech/abbott-eyes-structural-heart-gains-following-boston-scientifics-tavr-exit
33. Edwards risks TAVR market share slip amid challenges from Abbott, Boston Scientific: survey | MedTech Dive, https://www.medtechdive.com/news/edwards-tavr-market-share-challenges-abbott-boston-sci/705272/
34. Edwards Lifesciences Reports Second Quarter Results, https://www.edwards.com/newsroom/news/2026-07-23-edwards-lifesciences-reports-second-quarter-result-be3079f
35. Edwards Lifesciences Reports Second Quarter Results, https://ir.edwards.com/news/news-details/2026/Edwards-Lifesciences-Reports-Second-Quarter-Results/
36. Edwards posts strong TAVR sales ahead of potential Medicare coverage expansion, https://www.medtechdive.com/news/edwards-posts-strong-tavr-sales-ahead-of-potential-medicare-coverage-expans/826160/
37. Edwards Lifesciences names Doretta Mistras as new CFO - Investing.com, https://www.investing.com/news/company-news/edwards-lifesciences-names-doretta-mistras-as-new-cfo-93CH-4657416
38. UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 8-K EDWARDS LIFESCIENCES CORPORATION - Cloudfront.net, https://d18rn0p25nwr6d.cloudfront.net/CIK-0001099800/838f005d-503a-4c0f-8855-5cbd5172e317.pdf
39. New Edwards Lifesciences (NYSE: EW) CFO to receive $925K salary and major equity, https://www.stocktitan.net/sec-filings/EW/8-k-edwards-lifesciences-corp-reports-material-event-b6fe390827ac.html
40. Earnings call transcript: Edwards Lifesciences Q1 2025 beats EPS forecast - Investing.com, https://www.investing.com/news/transcripts/earnings-call-transcript-edwards-lifesciences-q1-2025-beats-eps-forecast-93CH-4000419
41. Edwards Lifesciences Reports Fourth Quarter Results | Nasdaq, https://www.nasdaq.com/press-release/edwards-lifesciences-reports-fourth-quarter-results-2025-02-11
42. Edwards reports strong 2025 despite Q4 EPS miss - Medical Device Network, https://www.medicaldevice-network.com/news/edwards-reports-strong-2025-despite-q4-eps-miss/
43. Edwards Lifesciences (EW) - Trefis, https://www.trefis.com/data/companies/EW
44. Edwards Lifesciences Reports First Quarter Results, https://ir.edwards.com/news/news-details/2025/Edwards-Lifesciences-Reports-First-Quarter-Results/
45. Edwards Lifesciences Reports Fourth Quarter Results - Business Wire, https://www.businesswire.com/news/home/20260210513744/en/Edwards-Lifesciences-Reports-Fourth-Quarter-Results
46. Edwards Lifesciences Reports Third Quarter Results, https://ir.edwards.com/news/news-details/2025/Edwards-Lifesciences-Reports-Third-Quarter-Results/default.aspx
47. Edwards Lifesciences (EW) Earnings Date and Reports 2026 - MarketBeat, https://www.marketbeat.com/stocks/NYSE/EW/earnings/
48. Earnings call transcript: Edwards Lifesciences Q4 2025 misses EPS forecast - Investing.com, https://www.investing.com/news/transcripts/earnings-call-transcript-edwards-lifesciences-q4-2025-misses-eps-forecast-93CH-4498472
49. Stock Information - Edwards Lifesciences Corp, https://ir.edwards.com/stock-information/default.aspx
50. Edwards Lifesciences (EW) - Shares outstanding - Companies Market Cap, https://companiesmarketcap.com/edwards-lifesciences/shares-outstanding/
51. Document - SEC.gov, https://www.sec.gov/Archives/edgar/data/1099800/000109980026000021/ex-991q12026.htm
52. Edwards Lifesciences Corporation (EWL) Leadership & Management Team Analysis, https://simplywall.st/stocks/de/healthcare/fra-ewl/edwards-lifesciences-shares/management
53. Edwards Lifesciences Corporation (EW) Stock Analysis: Navigating Growth With A 10% Upside Potential - DirectorsTalk Interviews, https://www.directorstalkinterviews.com/edwards-lifesciences-corporation-ew-stock-analysis-navigating-growth-with-a-10-upside-potential/4121260461
54. Edwards Lifesciences exec sells 620 shares after option exercise | EW Insider Trading, https://www.stocktitan.net/sec-filings/EW/form-4-edwards-lifesciences-corp-insider-trading-activity-4e2d49c5bbf3.html
55. EW SEC Filings - Edwards Lifesciences Corp 10-K, 10-Q, 8-K Forms - Stock Titan, https://www.stocktitan.net/sec-filings/EW/page-2.html
56. Edwards Lifesciences Corporation (EW) Stock Price, Quote, News & Analysis | Seeking Alpha, https://seekingalpha.com/symbol/EW
57. Edwards Lifesciences Corporation (EW) Stock Analysis: Strong Buy Ratings Signal 12.53% Upside Potential - DirectorsTalk Interviews, https://www.directorstalkinterviews.com/edwards-lifesciences-corporation-ew-stock-analysis-strong-buy-ratings-signal-12-53-upside-potential/4121259810